#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Metamizole as an Analgesic with a Favorable Benefit-Risk Ratio

Metamizole is a well-established and widely used molecule in many countries worldwide, suitable as an alternative to opioids for patients with moderate to severe acute or chronic pain. The popularity of this drug is associated not only with its efficacy but also with its safety, with no contraindications for patients with cardiovascular, renal, or gastrointestinal comorbidities.
Source: Analgesia 29. 3. 2023

News Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years

Dupilumab is now fully covered by public health insurance for pediatric patients from 6 years old with atopic dermatitis. This opens up a new possibility for pediatric patients with this condition to improve their quality of life.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 22. 1. 2022

News Indication of Bilastine in Specific Patient Groups −⁠ Practical Tips for Clinical Practice

Bilastine is a non-sedating H1-antihistamine, which is very well tolerated by patients. It can be indicated in the therapy of allergic diseases in both pediatric and adult populations. What are the possibilities of its use in specific patient groups?
Source: Allergic Reactions 24. 5. 2022

News Current Sequence of Treatment for Metastatic HER2+ Breast Cancer

In September 2023, experts from Miami Cancer Institute published their consensus statement on the treatment of HER2-positive advanced breast cancer (BC). The latest change in therapeutic strategy is the preference for the antibody-drug conjugate trastuzumab deruxtecan in the 2nd line.
Source: Ovarian and Breast Cancer 22. 2. 2024

News Depakine Chrono versus Other Valproates in the Treatment of Bipolar Disorder

Bipolar disorder is among the most severe psychiatric illnesses, and if not treated properly, it can negatively affect the patient's quality of life. Does switching therapy from other valproates to Depakine Chrono lead to better outcomes in treating this disease? The following study aimed to find the answer to this question.
Source: Bipolar Disorder 18. 11. 2020

News Pregabalin in the Treatment of Postherpetic Neuralgia Resistant to Gabapentin

Pregabalin appears to be an effective aid in patients with postherpetic neuralgia. This is evidenced by numerous clinical studies comparing the effects of pregabalin and gabapentin. It can be expected to alleviate painful symptoms and improve sleep quality, thereby significantly enhancing patients' quality of life.
Source: Neuropathic Pain 21. 5. 2021

News Impact of Rehabilitation on the Health of Patients with COPD

According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), pulmonary rehabilitation is one of the most effective therapeutic interventions for reducing dyspnea, improving physical performance, and enhancing quality of life. Below, we summarize current insights on the effectiveness and possibilities of rehabilitation for these patients.
Source: Treatment of Asthma and COPD 15. 11. 2022

News Incidence of CV Events, Malignancies, and Venous Thromboembolism in Patients with RA According to Baseline CV Risk and Administered Treatment

An international team of experts evaluated the impact of cardiovascular (CV) risk on the incidence and risk of major CV events, malignancies, and venous thromboembolism (VTE) in patients with rheumatoid arthritis (RA) treated with tofacitinib compared to tumor necrosis factor (TNF) inhibitors, depending on the level of CV risk at the initiation of this therapy. The authors used data from the ORAL Surveillance study.
Source: Arthritis 27. 7. 2022

News Retention –⁠ An Overlooked Parameter of Incontinence Products

In the Czech Republic and other European countries, the main criterion when choosing an incontinence product, apart from its size, is primarily absorption. This defines the amount of fluid the product can hold in its absorbent core, but it does not tell anything about its retention capability. What is retention and why is it important to know?
Source: Incontinence 9. 4. 2021

News Mass in the Left Atrium Appendage -⁠ Case Report

A symptomatic mass in the left atrial appendage warrants thorough investigation and radical treatment –⁠ unless it is in the heart of a polymorbid patient, as was the case in the following report.
Source: Thromboprophylaxis 14. 9. 2020

News How to Properly Treat Frostbite?

Frostbite, or congelation, is defined as an acute condition involving damage to the skin and subcutaneous tissues due to local cold, particularly at subzero temperatures. Treatment requires quality care. By choosing the right therapy, we can prevent complications that might otherwise threaten the patient with amputation of the affected part. The healing process is lengthy and requires patience from both the patient and the attending physician.
Source: Wound Healing 7. 12. 2021

News Benefit of Adding Erdosteine to Maintenance Treatment of COPD

Erdosteine is a mucoactive drug with anti-inflammatory, antioxidant, and anti-adhesive effects against bacteria, commonly used in the treatment of chronic obstructive pulmonary disease (COPD). In August 2022, another post-hoc analysis of the RESTORE study was published, evaluating the impact of its addition to COPD maintenance treatment on the incidence and severity of exacerbations and quality of life in patients with GOLD2 and GOLD3 grade bronchial obstruction.
Source: Cough Therapy 1. 11. 2022

News Does Sacubitril/Valsartan Prevent Myocardial Remodeling in Heart Failure Patients with Type 2 Diabetes?

The PROVE-HF study demonstrated reverse myocardial remodeling in patients with chronic heart failure with reduced ejection fraction. About 30–50% of heart failure patients have type 2 diabetes mellitus (DM2). The subject of a post hoc analysis of the PROVE-HF study was to find out whether this benefit of sacubitril/valsartan can be expected in patients with DM2 as well.
Source: Chronic Heart Failure and Lipidology 20. 5. 2021

News Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk

Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has been increasing in recent years. Currently, diabetics make up approximately 8−10% of the population. The therapy is traditionally focused primarily on suppressing the development and progression of diabetic complications, but modern antidiabetics have also brought other unprecedented benefits. The following text summarizes the role of gliflozins in the pharmacotherapy of DM2 in light of current recommendations.
Source: Heart Failure 20. 8. 2021

News What Benefits Do Modern Antidiabetics Bring to Patients in Primary Care?

How has the life of patients who now have the opportunity to treat diabetes mellitus in general practice changed? And what do the current prescription conditions for modern antidiabetics bring to their treating physicians? We discuss this and more with diabetologist MUDr. Katarína Nováková.
Source: Modern Treatment of Diabetes with GLP-1 Analogues 21. 6. 2024

1 59 60 61 62 63 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#